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Abstract
Type 1 iodothyronine deiodinase (DIO1) catalyses the conversion of prohormone thyroxine to the active thyroid hormone
3,39,5-triiodothyronine (T3), important regulator of cell proliferation and differentiation. DIO1 expression is reduced in the
most common type of kidney neoplasia, clear cell Renal Cell Carcinoma (ccRCC). MicroRNAs are small, non-coding RNAs that
regulate gene expression at posttranscriptional levels. The aim of this study was to analyze the potential regulation of DIO1
expression by microRNAs in ccRCC. Bioinformatic analysis revealed that 39UTR of the human DIO1 gene transcript contains
miR-224 and miR-383 target sites, which are conserved across mammalian species. Semi-quantitative real-time PCR was
used to analyze the expression of miR-224 and miR-383 in 32 samples of ccRCC tumors (T) and in 32 matched control (C)
samples. We observed statistically significant (p=0.0002) more than four fold increase in miR-224 expression and nearly two
fold increase in miR-383 expression in samples T compared to samples C. Tumor specific changes in expression of miR-224
negatively correlated with changes in DIO1 expression and intracellular T3 concentration. Transfection of HeLa cell line with
miR-224 and miR-383 suppressed the activity of a luciferase reporter containing the 39UTR of DIO1. This was abolished when
constructs mutated at the miR-224 and miR-383 target sites were used instead, indicating that miR-224 and miR-383 directly
bind to DIO1 39UTR. Finally, induced expression of miR-224 in Caki-2 cells resulted in significant (p,0.01) reduction of DIO1
mRNA. This study provides a novel miRNA-mediated regulatory mechanism of DIO1 expression in ccRCC.
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Introduction
Thyroid hormones: 3,5,39-L-triiodothyronine (T3) and thyrox-
ine (T4), play important roles in growth, development, differen-
tiation, and regulation of metabolic pathways in cells. Human type
1 iodothyronine deiodinase (DIO1), product of the DIO1 gene
catalyzes two types of deiodination reaction, an outer-ring (59-
deiodination - 59D) and an inner-ring (5-deiodination - 5D). These
processes result, respectively, in the activation and inactivation of
thyroid hormones (1). DIO1 is a selenoenzyme expressed mainly
in liver, kidney, thyroid, and pituitary. Previous reports have
shown that expression of this enzyme is disturbed in different types
of cancer. For instance, DIO1 mRNA and activity are decreased in
papillary thyroid carcinoma (2–5) and increased in follicular
adenoma and follicular thyroid carcinoma (2). In previous works
we showed decreased expression of DIO1 mRNA and activity (6),
and disturbed alternative splicing of DIO1 pre-mRNA in clear cell
Renal Cell Carcinoma (ccRCC) (7). DIO1 expression has also been
proposed as a differentiation marker of cancer cells (8, 9).
ccRCC represents the most common renal cancer histology,
representing 75% of primary malignancies of the kidney (10, 11).
The commonly used treatment is surgical resection while chemo-
and radiotherapy remain inefficient. None of the several proposed
molecular markers has been approved for clinical use (10).
MicroRNAs (miRNAs) are small, non-coding RNAs that
control genes expression by completely or partially complemen-
tarily binding to the 39-untranslated regiono ft a r g e tm R N A( 1 2 ,
13) causing degradation of the mRNA or, more commonly,
blocking translation (14–16). Previous studies have shown that
miRNAs play important roles in essential processes, such as
d i f f e r e n t i a t i o n ,p r o l i f e r a t i o n ,a n da p o p t o s i s( 1 7 ,1 8 ) .C u r r e n t l y
emerging results revealed that miRNAs are involved in cancer
pathogenesis. Frequent alterations of miRNA expression have
been found in a variety of human malignancies such as thyroid
(19), lung (20), pancreas (21), colon (22), breast (23), liver (24),
prostate (25) or other solid tumors (26, 27). Various studies have
identified panels of microRNAs that are differentially expressed
between normal renal tissue and tumor or between histological
subtypes of renal tumor (28–33). MicroRNA expression
profiling has shown diverse clinical applications for diagnosis,
prognosis and predictive purposes (34, 35). Several miRNAs
function as oncogenes or tumor suppressors, and multiple genes
coding for miRNAs are located in genomic regions involved in
cancers (36).
Our previous results (6) have shown that DIO1 activity poorly
correlates with its mRNA level in healthy renal tissues. This
observation suggests significant posttranscriptional regulation of
DIO1 expression that could be mediated by miRNAs. Therefore
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24541the aim of this work was to investigate the potential DIO1
regulation by miRNAs and to determine whether the deregulation
of DIO1 in ccRCC could result from altered actions of miRNAs.
Results
Computational prediction of miRNAs binding to DIO1
39UTR
To identify the putative miRNA targeting of the 39UTR of
DIO1 mRNA, we used computational programs, TargetScan,
PicTar, miRBase and miRANDA. The 1087 nucleotides of
39UTR of DIO1 were screened for complementarity to seed
sequences of known miRNAs. Only the miRNAs identified by at
least two of four independent bioinformatics approaches were
considered for further analysis. We identified 7 potential miRNAs
targeting the 39UTR of human DIO1 (Table 1): miR-224, miR-
383, miR-610, miR-659, miR-637, miR-1202 and miR-1266.
miR-224 and miR-383 are overexpressed in ccRCC
In preliminary studies, using semi quantitative real-time PCR
(SQ-PCR), we determined the relative expression of 7 candidate
miRNAs in ccRCC and paired match control samples from 32
patients using universal primer UniAmpHindIII (37) with
sequence homology to overhangs of primers used in reverse
transcription and miRNA-specific primers (sequences are shown in
Supplemental data, in Table S2). We observed differing expression
of miR-224 and miR-383, whereas expression of the five other
candidate miRNAs: miR-610, miR-637, miR-659, miR-1202 and
miR-1266 did not differ significantly between ccRCC and control
tissue (Figure S1, Supplemental Data).
Induced expression of miR-224 and miR-383 in ccRCC was
confirmed in a specific TaqMan microRNA assay. These studies
revealed statistically significant (p=0.0002) over four fold increase
in the expression of miR-224 and nearly two fold increase
(p=0.0236) in the expression of miR-383, in samples T compared
to control samples C (Figure 1). Mean fold change of miR-224 and
miR-383 was analyzed in different tumor gradings but did not
depend on the differentiation grade of tumor sample. However,
mean fold change of miR-224 tended to decrease when
differentiation grades increased from G1 to G3 (Figure 1).
Thus, disturbed expression of miR-224 and miR-383 in ccRCC
was confirmed by two different analytical approaches.
miR-224 negatively correlates with DIO1 and T3 levels in
ccRCC
SQ-PCR analysis revealed 2.7 fold downregulation of DIO1
mRNA in 32 paired tumor and control tissue samples (p=0.0009),
which is consistent with our previous reports (6) (Figure 2). As shown
in Figure 2, statistically significant negative correlation was observed
between miR-224 and DIO1 mRNA tumor-specific changes of
expression (Spearman rs=20.556 at p=0.001). In contrast, no
correlation was observed for miR-383 and DIO1.M o r e o v e r ,
Western-blot analysis performed on eleven paired samples of ccRCC
and normal kidney tissue revealed loss of DIO1 protein (Figure 2B).
DIO1 is a regulator of thyroid hormone bioavailability. In our
recent study we found that T3 concentration was decreased in ccRCC
tumors compared with pairmatched controls. To check whethermiR-
224-mediated downregulation of DIO1 affects DIO1 activity product,
T3, we analyzed the correlation between tumor-specific changes of
miR-224 and T3 levels. T3 levels were analyzed in 11 pair-matched
ccRCC and control samples that were used for DIO1 Western-blot
analysis. T3 concentration was assessed as described previously (37).
We found a statistically significant (Pearson r=20.624, p=0.04)
negative correlation between T: C ratios of miR-224 and intratumoral
T3 (Fig. 2). miR-383 changes did nor correlate with T3.
Lowered intratumoral T3 concentrations may result not only
from decreased expression of DIO1 but also from increased
activity of type 3 deiodinase (DIO3) which is a thyroid hormone
inactivating enzyme. Using Q-PCR, we analyzed expression of
DIO3 mRNA in 11 pair-matched ccRCC and control samples.
DIO3 mRNA was undetectable in all the analyzed samples (results
not shown). Thus, we confirmed that decreased intratumoral T3
concentrations result from lowered DIO1 expression.
Transfection with miR-224 decreases expression of
endogenous DIO1
To determine the functional effect of miR-224 and miR-383 on
endogenous DIO1 mRNA, Caki-2 cells were transfected with pre-
miR-224, pre-miR-383 (microRNA precursors), anti-miR-224,
anti-miR-383 (microRNA inhibitors), or scrambled control.
Successful transfection was confirmed in SQ PCR analysis by a
large induction of miR-224 and miR-383 after transfection with
microRNA precursors and significant decrease of miRNAs
expression when inhibitors were used (Figure 3).
mRNA levels of DIO1 were measured by SQ-PCR and a
significant reduction (56%, p,0.01) of the DIO1 transcript level
was observed after introduction of pre-miR-224. pre-miR-383 did
not have this effect (Figure 3). Transfection of Caki-2 cells with
anti-miR-224 resulted in increase of DIO1 expression, by 45%,
p,0.01, when compared with scrambled control. We did not
observe this overexpression when cells were transfected with anti-
miR-383 (Figure 3).
These data show that endogenous DIO1 mRNA expression in
Caki-2 cells is modulated by miR-224.
Table 1. Potential binding sites for microRNAs in 39UTR of DIO1 as determined by computational tools: TargetScan (T); miRBase
(B); PicTar (P); miRanda (R).
miRNA Coordinates Mature sequence Prediction method
hsa-miR-224 X:151127050-151127130[2] CAAGUCACUAGUGGUUCCGUU T, P, R
hsa-miR-383 8:14710947-14711019 [-] AGAUCAGAAGGUGAUUGUGGCU T, P, B
hsa-miR-610 11:28078362-28078457[+] UGAGCUAAAUGUGUGCUGGGA T, R
hsa-miR-637 19:3961412-3961510[2] ACUGGGGGCUUUCGGGCUCUGCGU B, R
hsa-miR-659 22:38243685-38243781[2] CUUGGUUCAGGGAGGGUCCCCA T, B
hsa-miR-1202 6:156267931-156268013[+] GUGCCAGCUGCAGUGGGGGAG T, R
hsa-miR-1266 15:52569314-52569397[+] CCUCAGGGCUGUAGAACAGGGCU T, R
doi:10.1371/journal.pone.0024541.t001
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383
Computational analysis of DIO1 39UTR with TargetScan5.1
revealed two putative binding sites for miR-224 and miR-383,
located at nucleotides 1788–1794 and 898–904 of DIO1 transcript
(NM_00792.5), respectively (Figure S2 in Supplemental Data).
These two sites were conserved across mammalian species. To study
the direct interaction between the miR-224, miR-383 and DIO1
transcript we cloned the 39UTR of DIO1 downstream of the
luciferase reporter gene in the pGL3-control vector – (DIO1-
39UTR). Control plasmid, in which DIO1 39 UTR was inserted in a
reverse orientation (DIO1-rev39UTR) was also constructed. In
parallel, we created two additional reporter constructs in which the
conserved targeting regions were specifically mutated, to abolish
binding of miRNAs (Figure 4). HeLa cell line, exhibiting low
endogenous expression of DIO1 was used for transfection experi-
ments. Cells were cotransfected with obtained constructs and
precursors of microRNAs: pre-miR-224, pre-miR-383 or control
(scrambled miRNA). In HeLa cells transiently transfected with the
DIO1-39UTR construct and miRNA precursors, a significant
inhibition of luciferase activity was observed. Both miR-224 and
miR-383 caused decrease in luciferase activity by about 45% and
25%, respectively, compared with the control scrambled miRNA.
Both pre-miRNAs failed to exert a significant effect on DIO1-
rev39UTR and the empty pGL3-Control vector (Figure 4).
The luciferase activity of the reporter constructs: DIO1-
39UTR224mut and DIO1-39UTR383mut, in which target sites
recognised by the microRNA were mutated, was unaffected by
transfection with pre-miR-224 or pre-miR-383, respectively
(Figure 4). This observation confirmed the specificity of action of
both microRNAs as mutation in the recognition site should
prevent from miRNA binding to 39UTR. What is more important,
mutation in the recognition site of one microRNA did not
influence binding of the other analyzed miRNA. The luciferase
activity in cells transfected with DIO1-39UTR383mut was
inhibited by 40% after pre-miR-224 addition, whereas transfection
Figure 1. Expression of miR-224 (A and B) and miR-383 (C and D) in ccRCC. A. Increased miR-224 expression in ccRCC tumor samples (T)
compared with control samples (C). The expression is shown as percentage of control C. B. Mean fold T: C change of expression of miR-224 224 in
samples divided according to tumor differentation grades (G1, G2, G3). C. Increased miR-383 expression in ccRCC tumor samples (T) compared to
control samples (C). The expression is shown as percentage of control C. D. Mean fold T: C change of expression of miR-383 224 in samples divided
according to tumor differentation grades (G1, G2, G3). Data are given as mean 6 SEM n=32 for T, n=32 for C (in A and C), n=11 for G1, n=11 for G2,
n=10 for G3 (in B and D). Statistical analysis was performed using paired t-test to compare C and T samples (in A and C) or ANOVA to compare G1,
G2, and G3 samples (in B and D)* p,0.05, *** p,0.001.
doi:10.1371/journal.pone.0024541.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24541Figure 2. miR-224 expression negatively correlates with DIO1 mRNA and T3 in ccRCC. A. Expression of DIO1 mRNA in tissue samples.
n=32 for T and n=32 for C. The expression is shown as percentage of control C. The plot shows median values with 95% CI as data were not
normally distributed. Statistical analysis was performed using Wilcoxon paired test to compare C and T samples. *** p,0.001. B. Western-blot of DIO1
performed on pair-matched control-ccRCC samples. b-actin expression was used as an internal control. Four representative control (C) and tumor (T)
samples are shown. C and D. Scatter plots of the T: C ratios of DIO1 mRNA versus T: C miR-224 (C) and T: C miR-383 (D) expression ratios. Non-
parametric Spearman’s rank correlation analysis was performed on data from 32 pairs of control and tumor tissue samples. p,0.05 was considered
statistically significant. E and F. Scatter plots of T3 concentration T: C ratio versus T: C miR-224 (E) and miR-383 (F) expression ratios. Pearson
correlation analysis was performed on data from 11 pairs of control and tumor tissue samples. p,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0024541.g002
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decrease in luciferase activity (Figure 4).
Takentogether,thesedatashowthatthe39UTRofDIO1 contains
specific binding sites for microRNAs miR-224 and miR-383.
Discussion
In this study we have shown for the first time that type 1
iodothyronine deiodinase transcript is a direct functional target for
microRNA miR-224. Binding of miR-224 to DIO1 39UTR results
in downregulation of endogenous DIO1 expression in renal cancer
cells. Moreover, DIO1 39UTR contains specific conserved binding
sites for miR-224 and miR-383, as showed in luciferase reporter
assays. Both microRNAs are markedly overexpressed in clear cell
renal cancer and possibly account for loss of DIO1 expression in
tumor. This has been supported by the negative correlation
between tumor-specific changes in miR-224 and DIO1 mRNA
levels and loss of DIO1 protein in ccRCC samples. Moreover,
tumor-specific changes in concentration of product of DIO1
activity, T3, correlate negatively with changes of miR-224
expression. These results provide a strong evidence for a novel
mechanism of DIO1 regulation.
Figure 3. miR-224 regulates endogenous DIO1 expression in Caki-2 cell line. A. Expression of DIO1 mRNA in the Caki-2 cell line. Cells were
transfected with 37.5 pmoles of pre-miRs, anti-miRs or scrambled pre-miR (negative control); after 48 h total RNA was extracted for subsequent SQ-
PCR analysis of DIO1 level. The expression is shown as percentage of control (cells transfected with scrambled microRNA). Data are given as mean 6
SEM. Data were analyzed by ANOVA followed by Dunnett’s multiple comparison test. ** p,0.01. B and C. The level of miR-224 (B) and miR-383 (C) in
cells transfected with pre-miRs or anti-miRs. Data are presented as percentage of control (cells transfected with scrambled microRNA). Data are given
as mean 6 SEM Values for miRNAs were normalized to U6 gene. Data were analyzed by ANOVA followed by Dunnett’s multiple comparison test.
*** p,0.001.
doi:10.1371/journal.pone.0024541.g003
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understood. In our previous studies we observed lack of correlation
between DIO1 protein and mRNA level in ccRCC (6) which
suggested the possible involvement of posttranscriptional mecha-
nisms, such as microRNA-dependent regulation. In the present
study we observed nearly 3-fold reduction of DIO1 mRNA
expression while DIO1 protein was lost in tumor samples. An
interesting observation made in the present study is that the
expression of miR-224 tends to change with tumor differentiation
grades and is highest in G1 and lowest in G3 (Fig. 2). Although
these changes between the respective tumor differentiation grades
are not statistically significant they may possibly suggest that as
tumor progress the impact of miR-224 on DIO1 expression lowers
and perhaps other posttranscriptional mechanisms are involved.
As we have previously shown, another mechanism contributing to
impaired DIO1 expression in ccRCC is its disturbed alternative
splicing resulting possibly from changes in expression of splicing
factors (7, 38). In the experiments performed in Caki-2 cells, miR-
383 did not affect the expression of endogenous DIO1. This may
suggest that miR-383 acts on a posttranscriptional level, causing
translation blockage rather than degradation of DIO1 mRNA. The
second possibility is that the other factors (including miR-224) may
exert stronger effect on DIO1 expression in ccRCC. This idea is
supported by results of luciferease experiments in which induced
miR-383 expression resulted in only 25% reduction of luciferase
activity in comparison with the effect of miR-224 which caused
45% downregulation of expression. Luciferase experiments
confirm the hypothesis that binding of miR-383 to DIO1 39UTR
results in translation blockage, as luciferase activity is a direct
consequence of actual luciferase protein levels.
Since altered expression of miR-224 and miR-383 was observed
in tumors of tissues expressing type 1 iodothyronine deiodinase it
suggests that these tumors may also present disturbed expression of
DIO1. Indeed, in papillary thyroid cancers, expression of miR-224
was significantly elevated (39) while our studies revealed that in
this cancer, expression of DIO1 is reduced (3). Conversely, in
breast cancer, miR-383 is lost (40) while DIO1 expression
significantly increases (41). Whether impaired expression of
DIO1 truly results from altered miR-224 and miR-383 levels in
these cancers needs to be evaluated by separate studies.
The significance of our findings comes from the role of DIO1 in
cellular physiology. DIO1 is an enzyme regulating bioavailability
of thyroid hormones. Recently it was suggested that DIO1 does
not contribute to circulating T3 levels but rather acts as a
scavenger enzyme involved in iodide recycling (42). However, the
possibility that DIO1 contributes to locally synthesized T3 in
DIO1 expressing tissues can not be ruled out as it was previously
suggested (43, 37). Thus, microRNAs regulating DIO1 expression
in ccRCC may have the potential influence on intratumoral
thyroid hormone levels. Indeed, as we demonstrate in the present
study, the tumor-specific changes in intracellular T3 concentration
correlate with changes of miR-224 expression. Interestingly, in our
recent study we found that transcript of thyroid hormone receptor
beta gene (THRB) is also a target for microRNA-dependent
regulation (37). miR-204 is overexpressed in ccRCC and results in
concomitant downregulation of THRB expression. These results
Figure 4. The DIO1 39UTR is the direct target for miR-224 and miR-383. A. DIO1 39UTR cloned downstream of luciferase in the pGL3-Control
vector. The wild-type and mutated 39UTR of DIO1 with the seed region (bold) and base substitutions (large font and underlined) abolishing binding
of a particular miRNA (verified in silico) are presented below. Two types of 39UTR mutants were constructed: DIO1-39UTR224mut and DIO1-
39UTR383mut. B. Dual luciferase assay. The relative luciferase activity of constructs with the 39UTR of DIO1: DIO1-39UTR, DIO1-rev39UTR, DIO1-
39UTR224mut, DIO1-39UTR383mut and pGL3-Control in the presence of pre-miRNA or scrambled pre-miRNA (negative control). Data are expressed as
mean values 6 SEM and are shown as percentage of control (cells transfected with scrambled microRNA). Each bar represents values from three
independent experiments, measured in triplicates. The relative activity of Firefly luciferase expression was normalized to Renilla luciferase activity.
Data were analyzed by ANOVA followed by Dunnett’s multiple comparison test. ** p,0.01.
doi:10.1371/journal.pone.0024541.g004
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microRNAs may possibly contribute to tissue hypothyroidism in
ccRCC resulting in downregulation of key genes of thyroid
hormone pathway, THRB and DIO1 and, in consequence, leading
to the the decrease of intratumoral T3 levels. This is an important
observation since several studies demonstrated that THRB can act
as a tumor suppressor and that hypothyroidism may influence
tumor growth (44–48). Thus, microRNA-dependent regulation of
intracellular thyroid state may possibly have the potential to affect
neoplastic process. Interestingly, this may be a more general
phenomenon in tumors with disturbed expression of DIO1 and
THRB. In our recent study several microRNAs that were
upregulated in papillary thyroid tumors (PTC) were shown to
directly target THRB transcript resulting in significant downreg-
ulation of its expression (49). It would be of interest to check
whether the expression of microRNAs targeting DIO1 is also
disturbed in PTC tumors. Our previous studies showed that loss of
DIO1 expression in PTC is accompanied by lack of correlation
between mRNA and protein expression (3). This suggests possible
posttranscriptional regulation including microRNA involvement.
However, whether impaired DIO1 expression in PTC results from
microRNA-mediated deregulation needs to be verified by further
studies.
Disturbed microRNA expression in ccRCC has already been
reported in other studies. Interestingly, among microRNAs
differently expressed in control and tumor samples miR-224 has
been repeatedly found by independent studies (30, 33, 50). This
suggests the possible use of miR-224 as a marker differentiating
ccRCC tumors from healthy tissues. Regarding miR-383, it was
reported as downregulated in hepatocellular carcinoma (51),
breast and ovarian cancers, melanoma (40), acute myeloid
leukemia (52) and central nervous system tumors (53). Thus, our
work is the first one showing upregulation of miR-383 in cancer.
Whether this is a specific feature of kidney neoplasia remains to be
verified by future experiments. Both microRNAs, miR-224 and
miR-383 are believed to be implicated in control of proliferation
or apoptosis. miR-224 was shown to increase apoptotic cell death
and proliferation in hepatocellular carcinoma (54) while overex-
pression of miR-383 inhibited proliferation of testicular embryonic
carcinoma cells (55). The question whether miR-224 and miR-383
are involved in ccRCC proliferation awaits future studies.
In summary, we demonstrated that DIO1 39UTR is targeted by
two microRNAs: miR-224 and miR-383. miR-224 mediates loss
of DIO1 in renal cancer, what results in decreased intratumoral
T3 concentration. These results provide a strong evidence for a
new mechanism regulating the expression of type 1 iodothyronine
deiodinase. Previous reports revealed that disturbed expression of
THRB, another gene of thyroid hormone pathway, observed in
ccRCC, may also result from microRNA-dependent deregulation.
Together, these results suggest that the new class of small, non-
coding RNAs may possibly contribute to intracellular hypothy-
roidism in ccRCC.
Materials and Methods
Tissue samples and cell lines
Tissue samples were obtained with the permission of the
Bioethics Committee of the Medical Centre of Postgraduate
Education in Warsaw from patients with clear cell renal cell
carcinoma (32 patients). Written informed consent was obtained
from all patients involved in this study. Samples were divided into
two groups: tumor samples (n=32, T) and control samples (paired
normal tissue from the opposite pole of the malignant kidney with
no histological evidence of tumor; n=32, C). Clear cell renal cell
carcinoma was diagnosed histologically according to WHO
criteria (56). Tumors were divided into three groups depending
on the grade of differentiation: G1 (well differentiated), G2
(intermediate grade of differentiation), G3 (poorly differentiated
cancers).
Cervical cancer (HeLa) and clear cell renal cell cancer (Caki-2)
cell lines used in this study were purchased from the American
Type Culture Collection, (USA) and cultured according to the
ATCC protocol. The cells were seeded into 12 well culture plates
at density 5610
4 (Caki-2) or 1610
5 (HeLa) cells/well 24 h before
transfection.
Luciferase Reporter Constructs
1023 bp fragment of DIO1 was amplified using cDNA from
HeLa cell line (primers DIO1-39UTR F and R, Table S1,
Supplemental data), cloned into XbaI-site immediately down-
stream of the stop codon in the pGL3-Control Firefly Luciferase
reporter vector (Promega, USA), sequenced and named DIO1-
39UTR, or DIO1-rev39UTR, depending on the orientation of the
cloned insert. The reversely inserted DIO1-rev39UTR was used as
negative control vector. Site-directed mutagenesis of the miR-224
and miR-383 target sites: GTGACTT of miR-224 within nt
1788–1794 and TCTGATCT of miR-383 within nt 898–904 in
the DIO1 39UTR was performed using Quick change-mutagenesis
kit (Stratagene, Germany). Primers Mut224 F/R and Mut383 F/
R (Table S1, Supplemental data) and DIO1-39UTR plasmid as a
template were used. Two constructs: DIO1-39UTR224mut and
DIO1-39UTR383mut were obtained.
Sequencing reaction was performed using BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, USA).
Cells transfection and luciferase assay
Caki-2 cells were seeded at 0.5610
5 cells per 12-well dish and
transfected 24 hours later using Lipofectamine 2000 reagent
(Invitrogen, USA) as described by the manufacturer with 37.5
pmoles of miRNA precursors: pre-miR-224 and pre-miR-383
(Pre-miR
TM
miRNA Precursor Molecule, Ambion, USA), miRNAs
inhibitors: anti-miR-224 and anti-miR-383 (Anti-miR
TM miRNA
Inhibitor Molecule, Ambion, USA) or control scrambled micro-
RNA (Negative microRNA Control, Ambion, USA). Cells were
harvested after 48 h for RNA extraction.
miRNA precursors are synthetic RNA duplexes that mimic
endogenous miRNAs, whereas inhibitors have a sequence
complementary to mature miRNAs and function by sequester-
ing/degrading endogenous miRNAs.
For reporter gene assays, HeLa cells were seeded at 1610
5 in
12-well plates and 24 h later, cotransfected with Lipofectamine
2000 reagent (Invitrogen, USA). Each cotransfection reaction
contained 100 ng pRL-TK vector (Promega, USA) expressing
Renilla luciferase, 1 ug of pGL-39 UTR vectors and 37.5 pmoles
of pre-miRs or scrambled microRNA. After 48 hours, cells were
lysed and luciferase activity was analyzed in dual-luciferase assay
(Promega, USA) using a Synergy2 luminometer (BioTek, USA).
Firefly luciferase activity was normalized to Renilla luciferase
activity. In all the experiments, transfection and luciferase assays
were performed in triplicates.
RNA isolation and reverse transcription
Total cellular RNA was isolated as described previously (37).
Reverse transcription was performed using RevertAidTM H
Minus First Strand cDNA Synthesis Kit (Fermentas, Lithuania).
For reverse transcription, 200 ng of total RNA was used with
Random Hexamer primers or specific stem-loop primers with 59-
overhangs (Table S2, Supplemental data) for microRNAs.
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specific miRNA primers from the TaqMan MicroRNA Assays
(Applied Biosystems, USA) and reagents from the TaqMan
MicroRNA Reverse Transcription kit (Applied Biosystems, USA).
SQ-PCR
DIO1 expression analysis in Caki-2 cells was performed using
DNA SYBR Green I Master (Roche Diagnostics, Germany) in
triplicates according to manufacturers’ protocols. SQ-PCR
reaction was carried out under the following conditions: 95uC
for 10 min., 45 cycles: 95uC, 15 s; 57uC, 15 s; 72uC, 15 s, 68uC,
15 s; followed by melting curve analysis: 95uC, 5 min.; 65uC,
1 min.; continuous reading of fluorescence from 65uCt o9 7 uC
with 0.11uC/s ramp rate and 5 acquisitions per each uC. Results
were normalized to the expression of 18sRNA host-gene RN18S1.
DIO1 and DIO3 expression analysis in tissue samples was
performed as described previously (37). The sequences of the
primers are shown in Table S1, (Supplemental data). For DIO3
expression, standard curve was performed using PCR product
cleaned with Clean-up kit (A&A Biotechnology, Poland).
SQ-PCR quantification of miRNAs was performed using
QuantiFast SYBR Green PCR Kit (Qiagen, Germany), universal
primer UniAmpHindIII with sequence homology to overhangs of
primers used in reverse transcription and miRNA-specific primers
(sequences are shown in Supplemental data, in Table S2).
Conditions for QuantiFast were as described (37).
To evaluate the expression levels of mature miRNA: 224 and
383 TaqMan MicroRNA Assay kits (Applied Biosystems, USA)
were used according to the manufacturer’s protocol. The assays
target only mature microRNAs, not their precursors, ensuring
biologically relevant results.
For normalization of miRNA expression, U6 snRNA was used
as an internal control. Relative quantification of each expressed
miRNA was calculated using the 2
2DCt method (57).
Western blot analysis
Isolation of protein and Western blot analysis was described
previously (37).
Tissue T3 concentration
Intracellular T3 concentration was analyzed previously (37).
Computational analysis
To predict miRNAs potentially binding to DIO1 39UTR
sequences we used commonly cited miRNA prediction programs:
TargetScan5.1 (http://www.targetscan.org/) (58), miRBase
(http://microrna.sanger.ac.uk/targets) (59), PicTar (http://pictar.
mdc-berlin.de/) (60) and miRanda (http://microrna.org) (61). We
considered microRNA as potentially binding to DIO1 39UTR only
if it was predicted by at least two of the four methods.
For examination of abolished binding between miRNAs and
DIO1-39UTR383mut or DIO1-39UTR224mut a miRNA target
detection tool (62) was used.
The analysis was performed based on the following reference
sequences: NCBI DNA Ref. Seq.: NC_000001.10: 21969 bp
(region from base 54357325 to 54379293). mRNA sequence:
NM_000792.5.
Statistical analysis
The Shapiro-Wilk test was used to determine normality of data
distribution. Most data were analyzed by t-test, while DIO1
expression in match-paired tissue samples was analyzed by
Wilcoxon matched pairs test. Correlation analysis was performed
with non-parametric Spearman’s rank correlation test. Data from
luciferase assays and transfection experiments were analyzed by
ANOVA followed by Dunnett’s multiple comparison test. p,0.05
was considered statistically significant.
Supporting Information
Table S1 Primers used for cloning, mutagenesis and
SQ-PCR analysis. SpeI restriction sites in primer
overhangs (underlined) are in bold.
(DOC)
Table S2 Primers used in analysis of miRNA. RT:
primers used in reverse transcription. PCR: primers used
in SQ-PCR. F: forward, R: reverse. Uni-amp sequences are
bolded.
(DOC)
Figure S1 Expression of microRNAs predicted to bind
to DIO1 39UTR in ccRCC. Expression of miR-224, miR-383,
miR-610, miR-637, miR-659, miR-1202 and miR-1266 was
analyzed in 32 matched pairs of tumor (T) and control (C)
samples. SQ-PCR reactions were performed in triplicates. The
expression is shown as percentage of control C. Data are given as
mean 6 SEM (n=32 for T, n=32 for C). Statistical analysis was
performed using t-test to compare C and T samples.
(TIF)
Figure S2 The microRNA target sites in DIO1 39UTR. A).
The structure of the human DIO1 transcript (GeneBank Acc. No.
NM_00792.5). The four exons are boxed, numbers above indicate
exon length. Stop codon indicates the beginning of 39UTR.
Binding sites of miR-383 and miR-224 are indicated and their
positions (miR-383: nt 898-904, miR-224: nt 1788–1794) are given
according to DIO1 mRNA sequence (NM_00792.5). B). Bioinfor-
matic prediction of miRNA binding sites in DIO1 39UTR,
conserved among six mammalian species performed with
TargetScan5.1.
(TIF)
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